ACST News and Press, Acasti Pharma Inc. From 07/07/23

Acasti Pharma Announces 1-for-6 Reverse Stock Split PR Newswire LAVAL, QB , July 7, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodi...

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023 PR Newswire STRIVE-ON is the pivotal Phase 3 trial of GTX-104 to evaluate its comparable safety ...

2023-06-23 16:05:53 ET Acasti Pharma press release ( NASDAQ: ACST ): FY GAAP EPS of -$0.95 misses by $0.53 . Cash, cash equivalents and short-term investments totaled $27.9 million as of March 31, 2023, compared to $43.7 million in cash, cash equivalents and short-term...

Acasti Pharma Reports Fiscal Year 2023 Operational Results PR Newswire LAVAL, Québec , June 23, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its no...

Acasti Announces Appointment of New Scientific Advisory Board Members PR Newswire LAVAL, QC , June 22, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel for...

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference PR Newswire LAVAL, QC , May 17, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its nov...

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025 PR Newswire Company successfully submits GTX-104 Pivotal Phase 3 protocol IND amendment to...

2023-04-04 08:38:51 ET Late-stage specialty pharma company advancing drug candidates for rare and orphan diseases, Acasti Pharma ( NASDAQ: ACST ) appoints Prashant Kohli as CEO, succeeding Jan D'Alvise. The parties have mutually agreed to part ways, and Ms. D'Alv...

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND PR Newswire Company expects the first patient to be enrolled during the second half of 2023 ...

Acasti Announces Appointment of Prashant Kohli as CEO PR Newswire LAVAL, QC , April 4, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage specialty pharma company advancing drug candidates for rare and orp...